Female participants of childbearing age must agree to remain abstinent or use reliable contraceptive methods during the treatment period, and at least  months after last dose of study drug
For women who are not postmenopausal and have not undergone surgical sterilization: agreement to remain abstinent or use two adequate non-hormonal methods of contraception, including at least one method with a failure rate of < percent (%) per year, during the treatment period and for a period of time after the last dose of study drug(s) as defined in the protocol
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < % per year during the treatment period and for at least  months after the last dose of atezolizumab/placebo or  months after the last dose of chemotherapy.
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a non-hormonal contraceptive method with a failure rate of <% per year during the treatment period and for at least  months after the last dose of atezolizumab and within  months after the last dose of cobimetinib
For women who are not postmenopausal or surgically sterile: agreement to remain abstinent or use contraceptive methods that result in a failure rate of less than (<)  percent (%) per year during the treatment period and for at least  months after the last dose of atezolizumab
For women of childbearing potential, agreement to remain abstinent (refrain from heterosexual intercourse) or use of contraceptive methods that result in a failure rate of less than (<)  percent (%) per year during the treatment period and for at least  days after the last study treatment
For women who are not postmenopausal and have not undergone surgical sterilization: agreement to remain abstinent or use two adequate non-hormonal methods of contraception including at least one method with a failure rate of <% per year during the treatment period and for at least five months after the last dose of atezolizumab and at least four months after the last dose of cergutuzumab amunaleukin, whichever is the longest
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < % per year during the treatment period and for at least  months after the last dose of study treatment;
For male subjects: agreement not to father a child. Participants must be surgically sterile (e.g, vasectomy) or use contraceptive methods that result in a failure rate of < % per year during the treatment period and for at least  months after the last dose of study treatment.
For women of childbearing potential: agreement to remain abstinent or use at least two forms of effective contraceptive with a failure rate of < % per year during the treatment period and for at least  months after the last dose of cobimetinib and at least  months after the last dose of atezolizumab or pembrolizumab
Women of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of ?% per year during the treatment period and for at least  months after the last dose of study treatment
For women of childbearing potential or male subjects: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < % per year, during the treatment period and for at least  months after the last dose of treatment
Male subjects are eligible to participate if they agree to the following during the intervention period and for at least  days: Refrain from donating sperm; Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; Agree to use a male condom and female partner to use an additional highly effective contraceptive method with a failure rate of < percent per year as when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < % per year during the treatment period and for at least  months after the last dose of RO as monotherapy, or for at least  months after the last dose of daratumumab.
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (<)  percent (%) per year during the treatment period and for at least  days after the last dose of guadecitabine or  months after the last dose of atezolizumab, whichever is longer
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < % per year during the treatment period and for at least  days after the last dose of atezolizumab or  months after the last dose of obinutuzumab, whichever is longer
For women of childbearing potential, agreement to remain abstinent (refrain from heterosexual intercourse) or use two effective forms of contraceptive methods including at least one that results in a failure rate of less than (<)  percent (%) per year during the treatment period and for at least  months after the last dose of study drug
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of <% per year, for at least  days prior to Day  of Cycle , during the treatment period (including periods of treatment interruption), and for at least  months after the last dose of study treatment
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < % per year during the treatment period and for  months after the last dose of study treatment
For women who are not postmenopausal (<  months of non therapy-induced amenorrhea, with no identified cause other than menopause) and have not undergone surgical sterilization (removal of ovaries and/or uterus): agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate non hormonal methods of contraception, including at least one method with a failure rate of < % per year, during the treatment period and for at least  months after the last dose of study drug
Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods among women of childbearing potential
For women who are not postmenopausal or surgically sterile: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than [<]  percent [%] per year during the treatment period and for at least  months after the last dose of study treatment for participants in the Atezo-G-benda and Atezo-G-CHOP treatment groups or for at least  months after the last dose of study treatment for participants in the Atezo-R-CHOP treatment group
For women who are not postmenopausal or surgically sterile: agreement to remain abstinent or to use contraceptive methods that result in a failure rate of less than (<) % per year during the treatment period for greater than or equal to (>=)  months after last dose of Atezo, >=  months after last dose of rituximab, >=  months after last dose of Pola, and >=  months after last dose of obinutuzumab
For men: agreement to remain abstinent or to use contraceptive measures that result in a failure rate of <% per year during the treatment period and for at least  months after last dose of obinutuzumab, rituximab, and Atezo and for  months after last dose of Pola, and agreement to refrain from donating sperm during this same period
For women of childbearing potential, agreement to refrain from heterosexual intercourse or use contraceptive methods that result in a failure rate of < % per year during the treatment period and for at least  months after the last dose of atezolizumab,  months after the last dose of vinflunine and  months from the last dose of paclitaxel or docetaxel.
For men, agreement to refrain from heterosexual intercourse or use contraceptive methods that result in a failure rate of < % per year during the treatment period and for at least  months after the last dose of vinflunine and  months from the last dose of paclitaxel or docetaxel, and agreement to refrain from donating sperm
For women who are not postmenopausal or surgically sterile: agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of < % per year during the treatment period and for at least  months after the last dose of study drug
For all participants, agreement to remain abstinent or use contraceptive methods that result in a failure rate of less than (<) % per year during the treatment period and for at least  days ( days for women) after the last dose of venetoclax or  months after the last dose of obinutuzumab, whichever is longer
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <% per year during the treatment period and for at least  months after the last dose of study drug
For women of childbearing potential: agreement to use contraceptive methods that result in a failure rate of < % per year during the treatment period and for at least  weeks after the last dose of idasanutlin
For women of childbearing potential: agreement to remain abstinent or use contraceptive methods with a failure rate of < % per year during the treatment period and for  months after the last dose of study treatment
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (<) % per year during the treatment period and for at least  months after the last dose of study drugs
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <% per year during the treatment period and for at least  months after the last dose of carboplatin, cisplatin, or gemcitabine or for  months after the last dose of atezolizumab